Patents by Inventor Donald Nash
Donald Nash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8613925Abstract: Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13R?1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13R?1-mediated activities are also disclosed.Type: GrantFiled: October 19, 2007Date of Patent: December 24, 2013Assignee: CSL LimitedInventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Patent number: 8574572Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor.Type: GrantFiled: August 10, 2007Date of Patent: November 5, 2013Assignee: CSL LimitedInventors: David Eric Crump, Andrew Donald Nash
-
Patent number: 8568722Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.Type: GrantFiled: May 6, 2010Date of Patent: October 29, 2013Assignee: CSL LimitedInventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Patent number: 8506960Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: GrantFiled: March 27, 2007Date of Patent: August 13, 2013Assignees: MedImmune Limited, Zenyth Operations Pty. Ltd.Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Publication number: 20120321630Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.Type: ApplicationFiled: June 13, 2012Publication date: December 20, 2012Applicant: CSL LIMITEDInventors: Andrew Donald NASH, Arna Elizabeth ANDREWS, Manuel BACA, Kirsten Mae EDWARDS, Matthew Philip HARDY, Con PANOUSIS, Felicity Meredith DUNLOP
-
Patent number: 8263075Abstract: Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis is also provided.Type: GrantFiled: March 27, 2007Date of Patent: September 11, 2012Assignee: MedImmune LimitedInventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Patent number: 8221755Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.Type: GrantFiled: July 1, 2010Date of Patent: July 17, 2012Assignee: Zenyth Operations Pty Ltd.Inventors: Felicity Meredith Dunlop, Manuel Baca, Andrew Donald Nash, Louis Jerry Fabri, Douglas James Hilton, Nicos A. Nicola
-
Patent number: 8207304Abstract: Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R? activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.Type: GrantFiled: October 19, 2007Date of Patent: June 26, 2012Assignee: CSL LimitedInventors: Andrew Donald Nash, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Publication number: 20120141464Abstract: Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid leukaemia and atherosclerosis is also provided.Type: ApplicationFiled: March 27, 2007Publication date: June 7, 2012Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Patent number: 8182814Abstract: The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.Type: GrantFiled: October 23, 2008Date of Patent: May 22, 2012Assignees: CSL Limited, Yale UniversityInventors: Manuel Baca, Andrew Donald Nash, Jack A. Elias
-
Publication number: 20110217366Abstract: The present invention provides an immunopotentiating composition which comprises an antigen or antigen-inducing substance, and a carrier comprising a biocompatible material for effectively increasing an immune response derived from an antigen. The present invention further provides a method of producing an antibody by administering said immunopotentiating composition to a mammal or bird, thereby modulating the immune response in said mammal or bird and recovering the antibody produced.Type: ApplicationFiled: May 17, 2011Publication date: September 8, 2011Applicants: Dainippon Sumitomo Pharma Co., Ltd., The University of Melbourne, KONEN CO., LTD.Inventors: Keiji FUJIOKA, Akihiko Sano, Shunji Nagahara, Malcolm Roy Brandon, Andrew Donald Nash, Shari Lofthouse
-
Publication number: 20110052597Abstract: Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13R?1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13R?1-mediated activities are also disclosed.Type: ApplicationFiled: October 19, 2007Publication date: March 3, 2011Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Patent number: 7895928Abstract: A shear device is disclosed. The shear device includes a material guiding mechanism, a shear head including a shear blade disposed proximate the material guiding mechanism, and a linkage for translating a first movement of one of the shear head and the material guiding mechanism into a second movement of the other of the shear head and the material guiding mechanism. A method is also disclosed.Type: GrantFiled: April 1, 2008Date of Patent: March 1, 2011Assignee: Flat Rock Metal Inc.Inventors: Michael Maloney, Donald Nash
-
Publication number: 20110020363Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.Type: ApplicationFiled: July 1, 2010Publication date: January 27, 2011Applicant: ZENYTH OPERATIONS PTY LTD.Inventors: Felicity Meredith DUNLOP, Manuel BACA, Andrew Donald NASH, Louis Jerry FABRI, Douglas James HILTON, Nicos A. NICOLA
-
Publication number: 20100285035Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.Type: ApplicationFiled: May 6, 2010Publication date: November 11, 2010Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Patent number: 7785590Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor ?1 chain (IL-13R?1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R?1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R?1/ligand interaction is also provided.Type: GrantFiled: May 20, 2004Date of Patent: August 31, 2010Assignee: Zenyth Operations Pty Ltd.Inventors: Felicity Meredith Dunlop, Manuel Baca, Andrew Donald Nash, Louis Jerry Fabri, Douglas James Hilton, Nicos A Nicola
-
Patent number: 7754213Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.Type: GrantFiled: October 19, 2007Date of Patent: July 13, 2010Assignees: Merck & Co., Inc., CSL LimitedInventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Publication number: 20090324591Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor.Type: ApplicationFiled: August 10, 2007Publication date: December 31, 2009Applicant: CSL LIMITEDInventors: David Eric Crump, Andrew Donald Nash
-
Publication number: 20090285799Abstract: Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.Type: ApplicationFiled: October 19, 2007Publication date: November 19, 2009Inventors: Andrew Donald Nash, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Publication number: 20090202533Abstract: The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.Type: ApplicationFiled: October 23, 2008Publication date: August 13, 2009Applicants: CSL Limited, Yale UniversityInventors: Manuel BACA, Andrew Donald NASH, Jack A. Elias